CLINICAL TRIALS PROFILE FOR GLIPIZIDE AND METFORMIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Glipizide And Metformin Hydrochloride
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00513630 ↗ | Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease | Completed | Shanghai Jiao Tong University School of Medicine | Phase 4 | 2004-06-01 | The purpose of this study is to explore the recurrence risk of cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease after different antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized, parallel control and prospective study The end point of this study is: 1. follow up 3yr 2. recurrence of cardiovascular event 3. death caused by other reasons such as stroke, uremia, blindness and amputation |
NCT00648505 ↗ | Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2005-06-01 | The objective of this study was to investigate the bioequivalence of Mylan's glipizide and metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fed conditions. |
NCT00649454 ↗ | Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2005-06-01 | The objective of this study was to investigate the bioequivalence of Mylan's glipizide and metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fasting conditions. |
NCT00660907 ↗ | Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients | Completed | Bristol-Myers Squibb | Phase 3 | 2008-03-01 | This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment. |
NCT00660907 ↗ | Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients | Completed | AstraZeneca | Phase 3 | 2008-03-01 | This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Glipizide And Metformin Hydrochloride
Condition Name
Clinical Trial Locations for Glipizide And Metformin Hydrochloride
Trials by Country
Clinical Trial Progress for Glipizide And Metformin Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Glipizide And Metformin Hydrochloride
Sponsor Name